Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission

Itai Levi*, Itamar Grotto, Ronit Yerushalmi, Isaac Ben-Bassat, Ofer Shpilberg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Abstract

In the present study, we have conducted a meta-analysis comparing autologous bone marrow transplantation (ABMT) and intensive chemotherapy in adult acute myeloid leukemia (AML) patients in first remission. Combined results of the six appropriate randomised controlled studies indicate that ABMT had no advantage over chemotherapy or no further treatment concerning death rate (overall rate ratio (RR) - 0.95, 95% CI, 0.81-1.11), while was superior to chemotherapy concerning event rate (overall RR - 0.82, 95% CI, 0.71-0.94). In conclusion, ABMT did not improve survival but it improved event-free survival (EFS) when compared with chemotherapy or no further treatment in patients with AML in first complete remission.

Original languageEnglish
Pages (from-to)605-612
Number of pages8
JournalLeukemia Research
Volume28
Issue number6
DOIs
StatePublished - Jun 2004

Keywords

  • ABMT
  • AML
  • Acute myeloid leukemia
  • Autologous bone marrow transplantation
  • CR
  • Complete remission
  • DFS
  • Disease-free survival
  • EFS
  • Event-free survival
  • HIDAC
  • High dose cytarabine
  • IDAC
  • Intermediate dose cytarabine
  • LFS
  • Leukemia-free survival
  • PBPC

Fingerprint

Dive into the research topics of 'Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission'. Together they form a unique fingerprint.

Cite this